Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town

被引：4

作者：

Hamelmann E. ^{[1
,2
]}

机构：

[1] Kinderzentrum Bethel, Evangelisches Klinikum Bethel, Grenzweg 10, Bielefeld

[2] Allergy Center of the Ruhr University, Bochum

来源：

Allergo Journal International | 2018年 / 27卷 / 7期

关键词：

Asthma; Children; Tiotropium; Treatment;

D O I：

10.1007/s40629-018-0066-y

中图分类号：

学科分类号：

摘要：

Background: Asthma is the most prevalent chronic airway disease observed in children and adolescents, yet the variety of treatment options available for this age group is limited. With many factors influencing therapeutic efficacy including patient knowledge, adherence, and therapy choice as well as delivery device, it is important to have more options to tailor to individual patient needs. Methods: This article is an overview of recent scientific articles using a systematic literature search in PubMed and specialist databases. Results: Tiotropium is the first long-acting muscarinic antagonist to be licensed for treatment of asthma and has been demonstrated to be an effective add-on therapy across all age groups. Its therapeutic success in clinical trials resulted in Food and Drug Administration and the European Medicines Agency approval for asthma treatment in people over the age of 6 years in the US and EU. Conclusion: Further studies into the use of tiotropium, especially in younger children, could be of interest for future treatment decisions. © 2018, The Author(s).

引用

页码：220 / 227

页数：7

共 50 条

[21] Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions
Adeeb Bulkhi
Farnaz Tabatabaian
Thomas B. Casale
Drugs, 2016, 76 : 999 - 1013
[22] An update on long-acting muscarinic agents for asthma therapy
Matera, Maria Gabriella
Cazzola, Mario
Rogliani, Paola
Patella, Vincenzo
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025,
[23] Synthesis of novel functionally selective and long-acting muscarinic antagonists
Mesa, Lilyveth
Martin, Chelsea
Boulos, John
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
[24] The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper
Agache, I.
Adcock, I. M.
Akdis, C. A.
Akdis, M.
Bentabol-Ramos, G.
van den Berge, M.
Boccabella, C.
Canonica, W. G.
Caruso, C.
Couto, M.
Davila, I.
Drummond, D.
Fonseca, J.
Gherasim, A.
del Giacco, S.
Jackson, D. J.
Jutel, M.
Licari, A.
Loukides, S.
Moreira, A.
Mukherjee, M.
Ojanguren, I.
Palomares, O.
Papi, A.
Perez de Llano, L.
Price, O. J.
Rukhazde, M.
Shamji, M. H.
Shaw, D.
Sanchez-Garcia, S.
Testera-Montes, A.
Torres, M. J.
Eguiluz-Gracia, I.
ALLERGY, 2025, 80 (02) : 380 - 394
[25] The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper
Semenzato, Umberto
Previtero, Daniele
Padrin, Ylenia
Baraldo, Simonetta
Tine, Mariaenrica
ALLERGY, 2025,
[26] Long-acting anticholinergics in the treatment of asthma
Guyer, Autumn Chandler
Long, Aidan Angelo
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 13 (04) : 392 - 398
[27] Effects of Treatment with Long-Acting Muscarinic Antagonists and Long-Acting Beta-Agonists on Lung Function Improvement in Patients with Bronchiectasis: An Observational Study
Lee, S.
Lee, J.
Lee, S.
Oh, Y.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[28] Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2 - agonists (LABA) for adults with asthma
Kew, Kayleigh M.
Evans, David J. W.
Allison, Debbie E.
Boyter, Anne C.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (06):
[29] Long-acting muscarinic M3 receptor antagonists -: GlaxoSmithKline
Norman, Peter
EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (09) : 1315 - 1320
[30] Long-acting muscarinic M3 receptor antagonists -: Theravance
Norman, Peter
EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (09) : 1321 - 1326

← 1 2 3 4 5 →